STOCK TITAN

Lisata Therapeutics (LSTA) Stock Price, News & Analysis

LSTA NASDAQ
Published by Stock Titan Data refreshed

Why Was LSTA Stock Down on Thursday?

7.15% on Thursday

Lisata Therapeutics (LSTA) announced a one-for-fifteen reverse stock split of its common stock effective November 23, 2026. Split-adjusted trading begins at the market open that day on The Nasdaq Capital Market under the existing symbol, LSTA.

Issued and outstanding common shares will fall from approximately 10.8 million to approximately 0.7 million. The number of authorized common shares and the par value per share will not change. Stockholders will receive cash instead of fractional shares. Ownership percentages will remain unchanged except for minor differences that may result from the treatment of fractional shares.

AI-generated explanation by Rhea-AI. How Rhea-AI works. Not financial advice.

Price Move History

Daily moves over 5%
58 252 sessions, November 19, 2025 to November 19, 2026
Largest daily move
+86.6% close of January 21, 2026
1-year change
-55.2% closing prices, November 19, 2025 to November 19, 2026
1-month change
-9% closing prices, October 19, 2026 to November 19, 2026

Company Description

Lisata Therapeutics, Inc. (Nasdaq: LSTA) is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for advanced solid tumors and other serious diseases. The company is centered around certepetide (formerly LSTA1), an investigational internalizing RGD (iRGD) cyclic peptide designed to activate a novel uptake pathway so that co-administered or tethered anti-cancer drugs can selectively target and penetrate solid tumors more effectively.

According to the company’s public disclosures, certepetide actuates a tumor-specific active transport system that enables systemically administered anti-cancer agents to penetrate and accumulate in tumors with greater efficiency. In addition to its drug delivery effects, certepetide has been shown to modify the tumor microenvironment, diminishing its immunosuppressive nature, enhancing cytotoxic T cell concentration and making tumors more susceptible to immunotherapies. Lisata and its collaborators report non-clinical and clinical data indicating enhanced efficacy and acceptable safety when certepetide is combined with existing and emerging therapies, including chemotherapies, immunotherapies, RNA-based therapeutics and antibody-drug conjugates (ADCs) in solid tumor models.

Core development focus: certepetide in solid tumors

Lisata states that it operates with a single primary development program built around certepetide. The company’s disclosures describe multiple ongoing or planned clinical studies in which certepetide is combined with standard-of-care (“SoC”) regimens across several solid tumor indications. These include metastatic pancreatic ductal adenocarcinoma (mPDAC), locally advanced non-resectable pancreatic ductal adenocarcinoma, cholangiocarcinoma, glioblastoma multiforme (GBM), and selected colon and appendiceal cancers.

Key certepetide-related programs described by Lisata include:

  • ASCEND: A Phase 2b double-blind, randomized, placebo-controlled trial in mPDAC, evaluating two dosing regimens of intravenous certepetide in combination with SoC chemotherapy (gemcitabine and nab-paclitaxel) versus SoC alone. The study is conducted across sites in Australia and New Zealand. Preliminary data from both dosing cohorts, as reported at oncology conferences, have shown positive trends in survival and response measures, with no increase in adverse events beyond those seen with SoC alone.
  • BOLSTER: A Phase 2a double-blind, placebo-controlled, multi-center randomized trial in the U.S. evaluating certepetide with SoC chemotherapy in first- and second-line cholangiocarcinoma. Lisata has reported completion of enrollment in first-line cholangiocarcinoma ahead of plan and the addition of a second-line cohort, with the goal of improving outcomes in patients who have progressed after first-line treatment.
  • CENDIFOX: An investigator-initiated Phase 1b/2a open-label trial in the U.S. at The University of Kansas Cancer Center, evaluating certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal cancers. Lisata reports that the trial is designed to generate pre- and post-treatment tumor tissue for immune profiling and long-term outcome data. Preliminary pancreatic ductal adenocarcinoma cohort results presented at a pancreatic cancer research conference indicated that combining certepetide with FOLFIRINOX was safe and feasible, with reported R0 resection and pathologic response rates, and evidence of tumors shifting from “immune-cold” to “immune-hot.”
  • iLSTA: A Phase 1b/2a randomized, single-blind, single-center safety and pharmacodynamic trial in Australia, funded by WARPNINE Inc., evaluating certepetide plus SoC chemotherapy (nab-paclitaxel and gemcitabine) and SoC immunotherapy (durvalumab) versus SoC alone in locally advanced non-resectable PDAC. Lisata and WARPNINE have announced completion of enrollment and preliminary data showing overall response and disease control rates that support the potential for certepetide to enhance immunotherapy effectiveness.
  • GBM study: A Lisata-funded Phase 2a double-blind, placebo-controlled, randomized proof-of-concept study evaluating certepetide in combination with SoC temozolomide versus SoC alone in newly diagnosed glioblastoma multiforme. The study is being conducted across sites in Estonia and Latvia, with plans to include an additional site in Lithuania.
  • Greater China license with Qilu Pharmaceutical: Qilu Pharmaceutical, as licensee of certepetide in the Greater China territory, is conducting a Phase 2 trial of certepetide plus gemcitabine and nab-paclitaxel as first-line treatment for mPDAC. Preliminary data shared at an oncology meeting were reported to corroborate earlier Australian trial findings, and Qilu has completed enrollment in its Phase 2 study.

Regulatory designations and technology platform

Lisata reports that certepetide has received multiple regulatory designations. These include Fast Track designation in the U.S. and Orphan Drug Designation for pancreatic cancer in both the U.S. and European Union. In the U.S., certepetide also holds Orphan Drug Designation for glioma, osteosarcoma and cholangiocarcinoma, as well as Rare Pediatric Disease Designation for osteosarcoma. These designations reflect regulatory recognition of the serious nature of the targeted diseases and the potential for certepetide-based approaches.

The company describes certepetide as the core of its CendR Platform® technology, which underpins both its internal clinical programs and external collaborations. Lisata states that it has established commercial and research and development partnerships that apply certepetide’s biology across different therapeutic modalities, including ADCs and AI-enabled drug discovery efforts.

Partnerships and collaborations

Lisata’s public communications highlight several notable collaborations:

  • Catalent, Inc.: Lisata has entered into a worldwide non-exclusive license agreement granting Catalent rights to use certepetide and its analogs as SMARTag® ADC payloads across multiple ADC programs designed for difficult-to-treat diseases. Under this agreement, Catalent assumes responsibility for research, development and commercialization costs. Lisata is eligible for development milestone payments and tiered revenue sharing on future sales and partnerships, as well as a share of certain sublicense consideration. Preclinical data presented by Catalent have shown that incorporating certepetide as a non-cytotoxic ADC payload can improve ADC efficacy and broaden the distribution of cytotoxic payloads within the tumor microenvironment.
  • GATC Health: Lisata has formed a strategic alliance with GATC Health to use GATC’s AI-powered Multiomics Advanced Technology™ platform. The collaboration is intended to optimize and accelerate drug discovery and development, including analyzing certepetide for new indications and identifying combination regimens.
  • WARPNINE Incorporated: In Australia, Lisata collaborates with WARPNINE, a not-for-profit clinical research organization, on the iLSTA trial in locally advanced non-resectable PDAC. Lisata provides drug supply and clinical strategy, while WARPNINE contributes funding support and operational execution at St John of God Subiaco Hospital.
  • Academic and regional partners: The ASCEND trial is led by the Australasian Gastro-Intestinal Trials Group (AGITG) and coordinated by the National Health and Medical Research Council Clinical Trial Centre at the University of Sydney. The CENDIFOX trial is conducted at The University of Kansas Cancer Center. The GBM study involves sites in Estonia and Latvia, with plans for an additional Lithuanian site. These collaborations provide access to specialized oncology centers and patient populations.

Intellectual property and corporate profile

Lisata has disclosed that the United States Patent and Trademark Office has issued a composition of matter patent for certepetide (U.S. Patent No. 12,351,653), covering its chemical structure, pharmacokinetic properties, manufacturing methods and applications in treating solid tumors. The patent extends certepetide’s protection into the next decade, with potential for further extensions, and grants Lisata exclusive rights to the drug substance.

The company is headquartered in Basking Ridge, New Jersey, and trades on the Nasdaq Capital Market under the symbol LSTA. Public filings and press releases indicate that Lisata is a clinical-stage entity with one primary operating segment focused on research and development of its investigational drug product. The company has reported maintaining a cash runway that it believes will fund operations into future periods, supporting ongoing clinical trials and partnership activities.

Role within oncology and drug development

Within the broader oncology landscape, Lisata positions certepetide as a potential enabling technology for multiple treatment modalities in solid tumors. By focusing on tumor-specific uptake pathways and modulation of the tumor microenvironment, the company aims to improve the performance of standard chemotherapies, immunotherapies, RNA-based therapeutics and ADCs in indications such as pancreatic cancer, cholangiocarcinoma and glioblastoma. Its collaborations with contract development and manufacturing organizations, AI-driven discovery platforms, non-profit research organizations and academic cancer centers reflect a model that combines internal development with external expertise.

Stock Performance

$0.9100
-7.15%
-0.0701
Last updated: at
-55.2%
Performance 1 year

Lisata Therapeutics (LSTA) closed at $0.9100 on November 19, 2026. Over the past 12 months, the price has lost 55.2%.

See what a $1,000 investment in LSTA would be worth today

Average down calculator for LSTA

LSTA Metrics & Rankings

Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Lisata Therapeutics has 10 recent news articles, with the latest published on . Of the recent coverage, 7 articles coincided with positive price movement and 2 with negative movement. Key topics include stock split, clinical trial, management, private placement, acquisition. View all LSTA news →

Financial Highlights

Lisata Therapeutics generated $170K in revenue in FY2025, operating income reached -$18.2M, and net income was -$16.6M. Diluted earnings per share stood at -$1.91. The company generated -$15.9M in operating cash flow. The current ratio was 5.76, measuring current assets divided by current liabilities.

$170K
Revenue (FY2025)
-$16.6M
Net Income (FY2025)
-$15.9M
Operating Cash Flow

Upcoming Events

NOV
23
November 23, 2026 Stock Split

Reverse stock split

One-for-fifteen reverse split effective 2026-11-23; split-adjusted trading begins at Nasdaq open under LSTA; fractional shares cashed.
Q4
2027
Q4 2027 Clinical

MAR001/005 topline data

Topline results from Phase 2b MAR001/005 in severe hypertriglyceridemia expected in Q4 2027; will inform next development steps.
Q4
2027
Q4 2027 Clinical

MAR002 topline data

Topline results from Phase 2 MAR002 in acromegaly expected in Q4 2027; results will guide regulatory and commercialization planning.
MAY
2041
May 2041 Corporate

Patent expiration

U.S. Patent No.12,751,991 covering certepetide combinations expires May 2041; affects exclusivity for pancreatic and solid tumors.

Lisata Therapeutics has 4 upcoming scheduled events. The next event, "Reverse stock split", is scheduled for November 23, 2026 (in 3 days). Investors can track these dates to stay informed about potential catalysts that may affect the LSTA stock price.

Short Interest History

Last 12 Months

Short interest in Lisata Therapeutics (LSTA) currently stands at 34.2 thousand shares, up 18.6% from the previous reporting period, representing 0.4% of the float. Since November 2025, short interest has increased by 90.5%.

Days to Cover History

Last 12 Months

Days to cover for Lisata Therapeutics (LSTA) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 5.2 days.

LSTA Company Profile & Sector Positioning

Lisata Therapeutics (LSTA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing LSTA often look at related companies in the same sector, including Allarity Therapeutics, Inc. (ALLR), Bolt Biotherapeutics, Inc. (BOLT), Seres Therapeutics, Inc. (MCRB), BioCardia, Inc. (BCDA), and Fractyl Health, Inc. (GUTS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate LSTA's relative position within its industry.

Frequently Asked Questions

The current stock price of Lisata Therapeutics (LSTA) is $0.9100 as of November 19, 2026.

The market cap of Lisata Therapeutics (LSTA) is approximately $9.8M. Learn more about what market capitalization means .

The FY2025 revenue of Lisata Therapeutics (LSTA) is $170K, from its most recent completed fiscal year.

The FY2025 net income of Lisata Therapeutics (LSTA) is -$16.6M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Lisata Therapeutics (LSTA) is -$1.91 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Lisata Therapeutics (LSTA) is -$15.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Lisata Therapeutics (LSTA), current assets divided by current liabilities, was 5.76 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Lisata Therapeutics (LSTA) is -$18.2M for FY2025, its most recent completed fiscal year. Learn about operating income.

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of therapies for advanced solid tumors and other serious diseases. Its work centers on certepetide, an investigational internalizing RGD cyclic peptide designed to help anti-cancer drugs selectively target and penetrate solid tumors more effectively.

Certepetide (formerly LSTA1) is described by Lisata as an internalizing RGD (iRGD) cyclic peptide product candidate. It is designed to activate a tumor-specific uptake pathway so that co-administered or tethered anti-cancer drugs can more efficiently penetrate and accumulate in solid tumors. Lisata also reports that certepetide can modify the tumor microenvironment, making tumors less immunosuppressive and more susceptible to immunotherapies.

According to Lisata’s public updates, certepetide is being evaluated in multiple solid tumor indications. These include metastatic pancreatic ductal adenocarcinoma in the ASCEND trial, locally advanced non-resectable pancreatic ductal adenocarcinoma in the iLSTA trial, cholangiocarcinoma in the BOLSTER study, pancreatic, colon and appendiceal cancers in the CENDIFOX trial, and glioblastoma multiforme in a Phase 2a proof-of-concept study. A licensee, Qilu Pharmaceutical, is also developing certepetide combinations in first-line metastatic pancreatic ductal adenocarcinoma in Greater China.

Lisata reports that certepetide has been granted Fast Track designation in the United States and Orphan Drug Designation for pancreatic cancer in both the U.S. and European Union. In the U.S., certepetide also holds Orphan Drug Designation for glioma, osteosarcoma and cholangiocarcinoma, as well as Rare Pediatric Disease Designation for osteosarcoma.

The CendR Platform® is Lisata’s term for the technology built around certepetide’s tumor-targeting and uptake biology. The company states that this platform underlies its internal clinical programs and external collaborations, enabling enhanced delivery and activity of various anti-cancer modalities, including chemotherapies, immunotherapies, RNA-based therapeutics and antibody-drug conjugates.

Lisata has entered into a worldwide non-exclusive license agreement with Catalent, Inc. that allows Catalent to incorporate certepetide and its analogs as SMARTag® ADC payloads in multiple antibody-drug conjugates. Catalent assumes responsibility for research, development and commercialization costs, while Lisata is eligible for development milestone payments, tiered revenue sharing on future sales and a share of certain sublicense consideration. Preclinical data presented by Catalent have shown that using certepetide as a non-cytotoxic ADC payload can improve ADC efficacy and broaden payload distribution within tumors.

Lisata has announced a strategic alliance with GATC Health to use GATC’s AI-powered Multiomics Advanced Technology™ drug discovery platform. The collaboration is intended to analyze certepetide for new indications, identify potential combination therapies and help optimize and accelerate drug discovery and development related to Lisata’s programs.

Lisata Therapeutics, Inc. is headquartered in Basking Ridge, New Jersey. Its common stock trades on the Nasdaq Capital Market under the ticker symbol LSTA.

Lisata has disclosed that the United States Patent and Trademark Office has issued U.S. Patent No. 12,351,653, a composition of matter patent covering certepetide. The patent’s claims include certepetide’s chemical structure, pharmacokinetic properties, methods of manufacturing and applications for treating solid tumors, and it grants Lisata exclusive rights to the drug substance for the life of the patent.

In its public press releases, Lisata has stated that it has cash, cash equivalents and related resources that it believes will fund current operations into future periods, including through anticipated data milestones from ongoing clinical trials. The company has also emphasized active management of operating expenses to extend its cash runway, while noting that these statements are forward-looking and subject to risks and uncertainties.